A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19

Brown et al., NCT04537806, NCT04537806, Jul 2022
ICU patientsDouble-blind RCT · NCT04537806 · 29 patients · USA
Brexanolone for COVID-19
Brown et al. NCT04537806 · July 2022
Outcome
Improvement
Relative Risk · 95% CI
No significant difference in outcomes seen
RCT 28 ventilated patients, showing no significant difference with brexanolone treatment.
Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments1. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments. This may explain in part the very high mortality seen in this study. Results may differ in countries with improved SOC.
OutcomeImprovementEffect · pTreatmentControl
risk of death 14.3% higher · RR 1.14 · p = 1.00 14.3% higherRR 1.14p = 1.00 8 of 14 (57.1%) 7 of 14 (50.0%) treatment 8 of 14 (57.1%), control 7 of 14 (50.0%)day 40
risk of death 33.3% higher · RR 1.33 · p = 0.71 33.3% higherRR 1.33p = 0.71 8 of 14 (57.1%) 6 of 14 (42.9%) treatment 8 of 14 (57.1%), control 6 of 14 (42.9%)day 28
respiratory failure or death 0.0% lower · RR 1.00 · p = 1.00 0.0% lowerRR 1.00p = 1.00 10 of 14 (71.4%) 10 of 14 (71.4%) treatment 10 of 14 (71.4%), control 10 of 14 (71.4%)day 28

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates.

Brown et al., 27 Jul 2022, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, trial NCT04537806 (history). Contact: info@sagerx.com.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2026 USA Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Jordan Georgia Switzerland Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia USA favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2026 USA Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Taiwan Fiji Zambia Jordan Georgia Switzerland Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia USA favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Late treatment
is less effective